Evidence map›Paper›PMID 27862226›Full record

ArticleJournal of cellular biochemistry2017

Histone H4 Methyltransferase Suv420h2 Maintains Fidelity of Osteoblast Differentiation.

Farzaneh Khani, Roman Thaler, Christopher R Paradise, David R Deyle, Marianne Kruijthof-de Julio, Mario Galindo, Jonathan A Gordon, Gary S Stein, Amel Dudakovic, Andre J van Wijnen

Open access · greenAbstract read
In one paragraph

Article in Journal of cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genetics and Epigenetics of Bone Remodeling and Metabolic Bone Diseases.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. RNA-seq in Skeletal Biology.Current osteoporosis reports · 2019
    Review
  14. Review
  15. Review
  16. Article
  17. Enhancer of zeste homolog 2 (The Journal of biological chemistry · 2018
    Article
  18. Epigenetics of Skeletal Diseases.Current osteoporosis reports · 2018
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Farzaneh KhaniDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Roman ThalerDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Christopher R ParadiseDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
David R DeyleDepartment of Medical Genetics, Mayo Clinic, Rochester, Minnesota.
Marianne Kruijthof-de JulioDepartment of Urology and Department of Clinical Research, University of Bern, Bern, Switzerland.
Mario GalindoFaculty of Medicine, Millennium Institute on Immunology and Immunotherapy, University of Chile, Santiago, Chile.
Jonathan A GordonDepartment of Biochemistry, University of Vermont College of Medicine, Burlington, Vermont.
Gary S SteinDepartment of Biochemistry, University of Vermont College of Medicine, Burlington, Vermont.
Amel DudakovicDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Andre J van WijnenDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USUniversity of Vermont · USBern University of Applied Sciences · CHMillennium Institute on Immunology and Immunotherapy · CL

Funding

Molecular Control of Bone FormationR01AR049069 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WESTENDORF, JENNIFER J · 2003 to 2021
$5.8M
In Vivo Gene Targeting to Treat Inherited Bone DiseaseR01AR067707 · NIAMS · MAYO CLINIC ROCHESTER · PI DEYLE, DAVID R · 2015 to 2020
$1.8M
Engineering Pluripotent Stem Cells to Treat Osteogenesis ImperfectaR03AR065753 · NIAMS · MAYO CLINIC ROCHESTER · PI DEYLE, DAVID R · 2014 to 2016
$239k
Epigenetic control of osteoblast differentiationF32AR066508 · NIAMS · MAYO CLINIC ROCHESTER · PI DUDAKOVIC, AMEL · 2015 to 2017
$185k
NIAMS NIH HHS F32 AR066508NIAMS NIH HHS R01 AR049069NIAMS NIH HHS R01 AR067707NIAMS NIH HHS R03 AR065753
6 · The paper itself

Abstract

Osteogenic lineage commitment and progression is controlled by multiple signaling pathways (e.g., WNT, BMP, FGF) that converge on bone-related transcription factors. Access of osteogenic transcription factors to chromatin is controlled by epigenetic regulators that generate post-translational modifications of histones ("histone code"), as well as read, edit and/or erase these modifications. Our understanding of the biological role of epigenetic regulators in osteoblast differentiation remains limited. Therefore, we performed next-generation RNA sequencing (RNA-seq) and established which chromatin-related proteins are robustly expressed in mouse bone tissues (e.g., fracture callus, calvarial bone). These studies also revealed that cells with increased osteogenic potential have higher levels of the H4K20 methyl transferase Suv420h2 compared to other methyl transferases (e.g., Suv39h1, Suv39h2, Suv420h1, Ezh1, Ezh2). We find that all six epigenetic regulators are transiently expressed at different stages of osteoblast differentiation in culture, with maximal mRNAs levels of Suv39h1 and Suv39h2 (at day 3) preceding maximal expression of Suv420h1 and Suv420h2 (at day 7) and developmental stages that reflect, respectively, early and later collagen matrix deposition. Loss of function analysis of Suv420h2 by siRNA depletion shows loss of H4K20 methylation and decreased expression of bone biomarkers (e.g., alkaline phosphatase/Alpl) and osteogenic transcription factors (e.g., Sp7/Osterix). Furthermore, Suv420h2 is required for matrix mineralization during osteoblast differentiation. We conclude that Suv420h2 controls the H4K20 methylome of osteoblasts and is critical for normal progression of osteoblastogenesis. J. Cell. Biochem. 118: 1262-1272, 2017. © 2016 Wiley Periodicals, Inc.

Indexed as

OsteogenesisAnimalsBiomarkersCell DifferentiationCell LineEpigenesis, GeneticHistone-Lysine N-MethyltransferaseHistonesMethylationMiceOsteoblastsSequence Analysis, RNABiomarkersHistone-Lysine N-MethyltransferaseHistonesKMT5C protein, humanBONEDIFFERENTIATIONEPIGENETICSEPIGENOMEHISTONEMETHYL TRANSFERASEOSTEOBLASTOSTEOCYTE

Identifiers

PMID27862226
PMCPMC5357582
OpenAlexW2549146077

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.